ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer

ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer

(MedPage Today) -- CHICAGO -- First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 2, 2025-

Pre-operative THP Achieves Pathological Complete Response in Two-Thirds of

In recent advancements within the realm of breast cancer therapy, the CompassHER2 pCR trial emerges as a beacon of hope by investigating a less intensive neoadjuvant chemotherapy regimen for early-stage HER2-positive breast cancer patients. This groundbreaking Phase II study rigorously evaluates the efficacy of 12 weeks of preoperative treatment consisting solely of the combination known as THP—a regimen integrating trastuzumab and pertuzumab, b…

Initial Enhertu Combo Improves Survival in HER2+ Advanced Breast Cancer

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, as per data from DESTINY-Breast09.

T-DXd/Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer

T-DXd plus pertuzumab significantly extended PFS (40.7 vs 26.9 months) in HER2+ metastatic breast cancer, suggesting a new frontline standard of care.

Frontline T-DXd Combo Elicits Meaningful PFS in HER2+ Advanced Breast Cancer

Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.